Introduction {#s1}
============

Mechanical thrombectomy (MT) is an evidence based treatment in acute stroke patients with large vessel occlusion (LVO) in the anterior brain circulation ([@B1]). It has been estimated that between 7 and 15% of all stroke patients could be candidates for MT ([@B2], [@B3]). However, data on rate, etiology and time-point of recurrent LVO after a first MT and outcome of repeated MT in such a scenario is scarce. To date, there are only a few case reports ([@B4]--[@B7]) and one retrospective study with 15 repeated MT due to recurrent LVO ([@B8]) which have addressed this issue. We therefore investigated time point, etiology and short-term outcome of repeated mechanical thrombectomy due to repeated LVO after a first MT with modern stent retrievers and thromboaspiration systems in a large tertiary neurovascular center.

Methods {#s2}
=======

We retrospectively reviewed all acute stroke patients treated with MT using modern stent retrievers and thromboaspiration systems at our tertiary neurovascular center between January 2010 and end of June 2018 and identified all patients who received two or more MT treatments due to a recurrent LVO in the anterior or posterior brain circulation. All patients received control brain imaging with computed tomography (CT) or magnetic resonance imaging (MRI) at 20--30 h, and color coded duplex sonography of the extra- and intracranial brain supplying blood arteries at 24--48 h after MT procedure. Additional CT or MRI angiography of the brain supplying arteries was performed in case of neurological deterioration after MT. All patients were treated on a specialized stroke unit or intensive care unit for at least 48 h with continuous ECG monitoring to detect atrial fibrillation after the MT procedure. Patient charts were evaluated regarding demographics, cardiovascular risk factors (hypertension, hyperlipidemia, diabetes mellitus, current smoking), atrial fibrillation, time elapse between the first and subsequent MT, use of antiplatelets or anticoagulants before and after the first and subsequent MT and stroke etiology. CT or MR imaging of the brain and brain supplying arteries (CT- or MR-angiography before the MT, digital subtraction angiography \[DSA\] and color coded duplex sonography) was reviewed by the authors for stroke etiology, hemorrhagic complications, reperfusion status using the Thrombolysis in Cerebral Infarction (TICI) score, and to assess vessel patency after MT. Stroke severity was scored using the National Institute of Health Stroke Scale (NIHSS) on admission and at discharge. The ethics committee of the Chamber of Physician North Rhine, Germany, approved the study.

Results {#s3}
=======

We identified 35 (1.4%) out of 2,470 acute ischemic stroke patients treated with MT who had two or more MT procedures due to recurrent LVO. Thirty-four patients were treated twice with MT and one patient three times. Mean age at the time of the first MT was 69.3 (± 15.8, range 28--86) years and 20 (57%) were female. The mean baseline NIHSS score at admission before the first MT was 12.6 ± 6.5 (range 1--31). Successful reperfusion (TICI score of 2b or 3) was achieved in all patients with the first MT procedure. None of the patients experienced an intracerebral hemorrhage on control imaging. The mean NIHSS score at discharge was 3.2 ± 4.6 (range 0--19). Twenty (57%) patients had a NIHSS score of 0 or 1 at discharge. The mean time interval between the first and second LVO was 147 ± 241 (range 0--872) days. The mean baseline NIHSS score at admission due to the second LVO was 12.8 ± 7.0 (range 2--32). Successful reperfusion (TICI score of 2b or 3) in repeated MT was achieved in 31/35 (89%) patients. Again, no intracerebral hemorrhage occurred. Seven (20%) of the 35 patients died after the repeated MT and the mean NIHSS score at discharge in the remaining 28 patients was 6.0 ± 8.0 (range 0--27). Seventeen (49%) of the 35 patients had a NIHSS score of 0 or 1 at discharge. Patient details are displayed in [Table 1](#T1){ref-type="table"}.

###### 

Detailed patient and procedural data.

  **Case**   **Age range**   **Time between procedures, days**   **Procedure**   **Site of vessel occlusion**   **Antiaggregation medication prior to mechanical thrombectomy**   **NIHSS at admission at discharge**   **Stroke etiology**
  ---------- --------------- ----------------------------------- --------------- ------------------------------ ----------------------------------------------------------------- ------------------------------------- --------------------------
  1          60--65          406                                 1st             M1 (R)                         None                                                              14 → 0                                AE
                                                                 2nd             ACI + M1 (R)                   Aspirin                                                           12 → 16                               
  2          75--80          2                                   1st             M1 (L)                         None                                                              13 → 7                                CE
                                                                 2nd             M1 (L)                         Aspirin                                                           12 → 16                               
  3          70--75          1                                   1st             M1 (R)                         None                                                              16 → 2                                CE
                                                                 2nd             M1 (R)                         Aspirin                                                           15 → death                            
  4          80--85          95                                  1st             M2 (L)                         Aspirin                                                           13 → 1                                Undetermined
                                                                 2nd             M2 (L) + A2                    Aspirin                                                           6 → 3                                 
  5          80--85          2                                   1st             M1 (L)                         None                                                              19 → 19                               CE
                                                                 2nd             BA                             Aspirin                                                           30 → 19                               
  6          85--90          42                                  1st             M1 (R)                         None                                                              15 → 0                                CE
                                                                 2nd             M1 (R)                         Clopidogrel                                                       9 → 9                                 
  7          55--60          115                                 1st             M2 (L)                         VKA (INR 1.7)                                                     7 → 0                                 CE
                                                                 2nd             M2 (L)                         None                                                              6 → 1                                 
  8          70--75          490                                 1st             M1 (L)                         None                                                              10 → 1                                CE
                                                                 2nd             M1 (R)                         Aspirin                                                           n.a.                                  
  9          80--85          3                                   1st             ICA-T (L)                      Aspirin                                                           21 → 12                               CE
                                                                 2nd             M1 (R)                         Aspirin                                                           25 → death                            
  10         80--85          15                                  1st             M1 (L)                         Aspirin                                                           11 → 2                                CE
                                                                 2nd             M1 (R)                         Aspirin                                                           10 → 1                                
  11         60--65          5                                   1st             M1 (L)                         None                                                              15 → 2                                LA
                                                                 2nd             M2 (L)                         Aspirin                                                           17 → death                            
  12         40--45          17                                  1st             M1 (R)                         Aspirin                                                           20 → 1                                AE
                                                                 2nd             M1 (R)                         Aspirin                                                           8 → 0                                 
  13         80--85          7                                   1st             M2 (L)                         Aspirin                                                           9 → 4                                 CE
                                                                 2nd             BA                             Aspirin                                                           31 → death                            
  14         75--80          17                                  1st             ICA (L) + M1 (L)               Aspirin                                                           8 → 7                                 1st MT: AE
                                                                 2nd             ICA (L)                        Aspirin + Clopidogrel                                             15 → 27                               2nd MT: CE
  15         75--80          872                                 1st             M1 (R)                         None                                                              7 → 0                                 CE
                                                                 2nd             Distal ICA (R)                 Aspirin                                                           11 → 1                                
  16         75--80          20                                  1st             ACI + M1 (R)                   Aspirin                                                           18 → 8                                Undetermined
                                                                 2nd             M1 (L)                         Aspirin                                                           19 → 19                               
  17         35--40          20                                  1st             M1 (L)                         None                                                              12 → 5                                Factor V Leiden mutation
                                                                 2nd             M1 (R)                         Aspirin                                                           12 → 1                                
  18         35--40          719                                 1st             BA                             Clopidogrel                                                       30 → 14                               AE
                                                                 2nd             V4 (L+R) + BA                  Aspirin + Clopidogrel                                             6 → 2                                 
  19         70--75          1                                   1st             M1 (R)                         Aspirin + Clopidogrel                                             15 → 9                                CE
                                                                 2nd             M1 (L)                         Aspirin + Clopidogrel                                             9 → 10                                
  20         70--75          5                                   1st             M1 (L)                         n.a.                                                              20 → 4                                undetermined
                                                                 2nd             M2 (R)                         Aspirin                                                           9 → 2                                 
  21         75--80          246                                 1st             ICA-T (R)                      Aspirin                                                           15 → 0                                undetermined
                                                                 2nd             ICA-T (L)                      Aspirin                                                           20 → death                            
  22         80--85          612                                 1st             M2 (L)                         VKA (INR 1.4)                                                     12 → 1                                CE
                                                                 2nd             A1 (L)                         VKA (INR 2.7)                                                     12 6                                  
  23         80--85          575                                 1st             M1 (R)                         VKA (INR 1.7)                                                     6 → 0                                 1st MT: CE
                                                                 2nd             CCA (L) + M2 (L)               VKA (INR 1.9)                                                     12 → 3                                2nd MT: AE
                             2                                   3rd             A1 (L) + M3 (L)                Aspirin                                                           3 → death                             3rd MT: CE
  24         70--75          186                                 1st             M1 (L)                         Aspirin                                                           21 → 0                                Undetermined
                                                                 2nd             M1 (R)                         Aspirin + Clopidogrel                                             9 → 0                                 
  25         70--75          357                                 1st             AV (R)                         VKA (INR 4.5)                                                     2 → 0                                 1st MT: AE
                                                                 2nd             M2 (L)                         VKA (INR 1.2)                                                     7 → 0                                 2nd MT: CE
  26         60--65          5                                   1st             SCA (R)                        None                                                              1 → 1                                 AE
                                                                 2nd             BA                             Aspirin + Clopidogrel                                             30 → 5                                
  27         35--40          4                                   1st             ICA (L) + M1 (L)               None                                                              18 → 7                                Undetermined
                                                                 2nd             ICA-T (L)                      Aspirin                                                           14 → 3                                
  28         75--80          93                                  1st             M1 (R)                         None                                                              11 → 0                                AE
                                                                 2nd             M1 (R)                         DOAC                                                              16 → 0                                
  29         75--80          2                                   1st             ICA (R) + M1 (R)               NMWH                                                              12 → 3                                CE
                                                                 2nd             M2 (L)                         Aspirin                                                           20 → death                            
  30         65--70          35                                  1st             ICA (L) + M1 (L)               None                                                              11 → 0                                AE
                                                                 2nd             CCA + ICA (L)                  None                                                              6 → 0                                 
  31         55--60          18                                  1st             M1 (R)                         None                                                              14 → 0                                AE
                                                                 2nd             M1 (R)                         Aspirin                                                           6 → 0                                 
  32         75--80          5                                   1st             M1 (L)                         NMWH                                                              8 → 1                                 CE
                                                                 2nd             M1 (R)                         DOAC                                                              12 → 0                                
  33         75--80          0                                   1st             M1 (R)                         Aspirin                                                           15 → 0                                CE
                                                                 2nd             M1 (L)                                                                                           16 → 0                                
  34         25--30          0                                   1st             VA (L) + BA                    None                                                              2 → 0                                 AE
                                                                 2nd             BA                             Aspirin                                                           4 → 0                                 
  35         70--75          15                                  1st             M1 (R)                         Aspirin                                                           1 → 0                                 Undetermined
                                                                 2nd             M1 (L)                         Aspirin                                                           11 → 20                               

*Age range instead of the exact patient age is presented in order to minimize identifiable patient data*.

*NIHSS, National Institutes of Health Stroke Scale; MT, mechanical thrombectomy; M1, M1 segment of the middle cerebral artery; M2, M2 segment of the middle cerebral artery; A1, A1 segment of the anterior cerebral artery; CCA, common carotid artery; ICA, internal carotid artery, ICA-T, internal carotid artery terminus; SCA, superior cerebellar artery; VA, vertebral artery; BA, basilar artery; (R), right; (L), left; AE, arterioembolic; CE, cardioembolic; OAC, oral anticoagulation; VKA, vitamin K antagonist; INR, international normalized ratio; DOAC, direct oral anticoagulant; NMWH, non-molecular weight heparin; n.a., not assessed*.

Stroke etiology could be identified in 28 (80%) of the 35 patients with recurrent LVO receiving MT. A cardioembolic cause was found to cause the first and recurrent LVO in 15 (43%) patients (13 patients with atrial fibrillation, one patient with mechanical aortic valve, and one patient with ventricular cardiac thrombus after coronary artery bypass grafting). All 15 patients with cardioembolic stroke had no or insufficient oral anticoagulation (OAC) at the time of their first LVO stroke, while 13/15 of these patients did also have no or insufficient OAC at the time of their recurrent LVO stroke. Nine (26%) patients had an arterioembolic cause with recurrent LVO stroke in the same vessel territory: large-artery extra- (*n* = 4) or intracranial (*n* = 2) atherosclerotic stenosis, arterial dissection in 2 patients, and carotid artery web in 1 patient. Two patients received a carotid stenting in the session of the second MT and the vertebral artery was artificially closed in two other patients to prevent recurrent embolization. Carotid endarterectomy was performed in one patient after the second MT procedure. There were three (9%) patients with a mixed cardio- and arterioembolic stroke etiology of the first and recurrent LVO stroke, and stenting was performed in these patients. One patient with contralateral recurrent LVO had heterozygous factor V Leiden mutation. Stroke etiology could not be identified in 7 (20%) patients despite intensified evaluation after both the first and second LVO stroke including holter ECG recording for at least 3 days and transesophageal echocardiography. Five of these seven patients with embolic stroke of undetermined source had contralateral recurrent LVO suggesting a cardioembolic stroke cause.

The mean age of 78 ± 7 (range 57--86) years in the 15 patients with cardioembolic strokes was substantially higher compared to 55 ± 17 (range 28--76) years in the 9 patients with arterioembolic stroke. Seven (47%) of 15 recurrent LVO in patients with cardioembolic stroke occurred during the first 3 days after the first MT, while only 1/9 (11%) patients in the group with arterioembolic stroke had a very early recurrent LVO. The median time interval between the first and subsequent LVO stroke was 5 (range 0--872) days in cardioembolic and 18 (0--719) days in arterioembolic stroke.

Discussion {#s4}
==========

Our retrospective case series is the largest study to date that investigated time point, etiology, and short-term outcome of repeated MT due to recurrent LVO stroke. Overall, repeated MT was performed rarely (1.4% of all MT procedures) in our large volume neurointerventional center. This finding was in line with another retrospective case series from a large neurointerventional center in the US ([@B8]). These authors reported that 15 (2%) of 697 patients with LVO stroke had repeated MT. However, it is likely that we have missed patients with recurrent LVO stroke after first MT as our study was not population based and several factors may have contributed to an underestimation of repeated MT. First, all but one patient in our study showed a considerable improvement of their baseline NIHSS after the first MT. Patients with no clinical improvement or no successful reperfusion after the first MT are probably more likely not be regarded as candidates for repeated MT in case of recurrent LVO. Second, stroke patients with recurrent LVO stroke might have presented to other stroke center in our metropolitan area.

Rates of successful recanalization were high both for the first and repeated MT procedures. There were no asymptomatic or symptomatic intracranial bleeding complications in LVO stroke patients treated with repeated MT, underlining again the safety and effectiveness of such a procedure. Not unexpected, early neurological improvement occurred slightly less frequently after second MT (47 vs. 57%) and in-hospital mortality rate was 20% after second MT. Bouslama et al. also reported that 20% of their stroke patients treated with repeated MT were deceased at 90 days ([@B8]). We are not able to report long-term functional outcome at a predefined time point in all patients (i.e., modified Rankin scale at 3 months), which is another limitation of our retrospective study.

Almost all LVO stroke patients with cardioembolic etiology had no or no sufficient OAC at the time of their first and recurrent LVO. Fifty percent of the recurrent cardioembolic LVO strokes occurred in the first 3 days after the successful initial MT procedure. This finding confirms the recommendation of subsequent stroke unit treatment of MT patients for at least 72 h to detect early LVO stroke recurrence as fast as possible ([@B9]). Furthermore, current guidelines do not provide evidence-based recommendations on optimal time-point to start OAC after acute ischemic stroke. All randomized trials with non-vitamin K antagonist oral anticoagulants start treatment at 14 days after the index stroke. Our data support the need to investigate whether OAC should be started earlier in acute stroke patients ([@B10], [@B11]).

Since five of the seven recurrent LVO in patients with unknown stroke etiology occurred contralateral to the first LVO, a cardioembolic stroke etiology (i.e., paroxysmal atrial fibrillation) is highly presumed, especially in patients older than 70 years. Patients with arterioembolic stroke were substantially younger and all recurrent LVO occurred in the same arterial vessel territory.

In conclusion, repeated MT in LVO stroke is a rare condition and can be performed safely with a high effectiveness. Cardioembolic stroke with no or no sufficient OAC was the most frequent cause for recurrent stroke due to LVO.
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